2017 Practice News
The latest news and research on allergic diseases and asthma were unveiled at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) held in Boston at the end of October. More information on the most noteworthy studies presented are available here.
We are proud to announce we have been voted "Best Allergy Care" by the Atlanta community through Best Self Magazine's “Best of 2017” contest.
Atlanta Allergy & Asthma is proud to support the Immune Deficiency Foundation and their Annual IDF Walk for Primary Immunodeficiency, Saturday October 28th at Brook Run Park in Dunwoody.
Shire is sponsoring a dinner program to help Primary Immunodeficiency patients and their caregivers navigate insurance coverage and reimbursement.
September 28th is National Penicillin Allergy Day! Learn about the symptoms and how you can get tested to see if you have a penicillin allergy.
To better serve the Alpharetta community, Atlanta Allergy & Asthma’s Alpharetta office has relocated.
Drs. Stanley M. Fineman, Erinn T. Gardner, Linda D. Guydon, Kevin L. Schaffer, Kathleen A. Sheerin, David D. Tanner, John A. Zora appear in Atlanta magazine’s July issue
For adult patients with Hereditary Angioedema (HAE), Shire is sponsoring an educational dinner event on Tuesday, August 15th at The Atlanta Fish Market.
Our Douglasville office was chosen as "Best Allergy Care" in Douglas County in the "2017 Reader's Choice" contest sponsored by the Douglas County Sentinel.
The 20th Allergy & Asthma Network Day on Capitol Hill (AADCH) is taking place Thursday, May 4, 2017, in Washington, D.C.
Atlanta Allergy & Asthma patients who have EpiPens, please be aware the recall has expanded to include lots distributed in the U.S.
Mylan has announced its manufacturing partner Meridian Medical Technologies expanded a voluntary recall of select lots of EpiPen® and EpiPen Jr.® epinephrine auto-injectors to the United States.
On Jan. 5, updated guidelines from the National Institute of Allergy and Infectious Diseases (NIAID) defined high-, moderate- and low-risk infants for developing peanut allergy, and how to proceed with the introduction of peanut-containing foods based on risk.